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mRNA processingCholinergic signaling suppresses inﬂammation in blood and brain and attenuates apoptosis in other tissues, but
whether it blocks inﬂammation in skeletal muscle under toxicant exposure, injuries and diseases remained
unexplored. Here, we report nicotinic attenuation of inﬂammation and alteration of apoptotic protein expression
pattern in murine muscle tissue and cultured myotubes, involving the RNA-binding protein, Tristetraprolin, and
the anti-apoptotic protein,Mcl-1. Inmuscles and C2C12myotubes, cholinergic excitation by exposure to nicotine
or the organophosphorous pesticide, Paraoxon, induced Tristetraprolin overproduction while reducing pro-
inﬂammatory transcripts such as IL-6, CXCL1 (KC) and CCL2 (MCP-1). Furthermore, nicotinic excitation under
exposure to the bacterial endotoxin LPS attenuated over-expression of the CCL2 and suppressed the transcrip-
tional activity of NF- B and AP-1. Tristetraprolin was essential for this anti-inﬂammatory effect of nicotine in
basal conditions. However, its knockdown also impaired the pro-inﬂammatory response to LPS. Finally, in vivo
administration of Paraoxon or recombinant Acetylcholinesterase, leading respectively to either gain or loss of
cholinergic signaling, modiﬁed muscle expression of key mRNA processing factors and several of their
apoptosis-related targets. Speciﬁcally, cholinergic imbalances enhanced the kinase activators of the Serine–Arginine
splicing kinases, Clk1 and Clk3. Moreover, Paraoxon raised the levels of the anti-apoptotic protein, Mcl-1,
through a previously unrecognized polyadenylation site selection mechanism, producing longer, less stable
Mcl-1 mRNA transcripts. Together, our ﬁndings demonstrate that in addition to activating muscle function, ace-
tylcholine regulates muscle inﬂammation and cell survival, and point to Tristetraprolin and the choice of Mcl-1
mRNA polyadenylation sites as potential key players in muscle reactions to insults.
© 2011 Elsevier B.V. Open access under CC BY-NC-ND license. 1. Introduction
Muscle injuries and skeletal muscle diseases notably involve en-
hanced inﬂammation and apoptosis [1,2]. Acetylcholine (ACh) is the
sole neurotransmitter in the neuromuscular junction (NMJ), where it
binds to muscle nicotinic ACh receptors with the consequent depolari-
zation of the muscle ﬁber, opening of voltage-gated Na+ channels,
and the triggering of an action potential in the ﬁber [3]. This processinesterase; AChE-R, Acetylcho-
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icroRNA; NMJ, neuromuscular
NA 3′ ends; shRNA, short hair-
es and The Biodesign Institute,
5287-4501, USA. Tel.: +1 480
ogical Chemistry, The Hebrew
ivat Ram, Jerusalem 91904, Is-
req@cc.huji.ac.il (H. Soreq).
-NC-ND license. terminates when ACh is hydrolyzed by the enzyme Acetylcholinester-
ase (AChE). Therefore, AChE inhibitors such as organophosphorous
nerve agents and pesticides enhance cholinergic signaling by potentiat-
ing the effect of a discrete quantity of ACh [4].
In other tissues, AChwas shown to regulate both inﬂammation [5,6]
and cell death [7,8]. However, whether cholinergic signaling controls
inﬂammation and apoptosis in skeletal muscles is yet unknown. Recent
evidence suggests that skeletal muscles not only respond to immuno-
logical signals, but also operate as an active immunological tissue [9].
Muscle cells can act as antigen presenting cells [10] and express a rich
repertoire of cytokines, chemokines (e.g. CCL2 (MCP-1) and CXCL1
(KC)) and their receptors [11]. For example, both type I and type II mus-
cle ﬁbers express IL-6 in response to muscle contractions, which then
mediates exercise-induced inﬂammatory and metabolic effects [12]. In-
deed, high levels of pro-inﬂammatory cytokines were observed in Duch-
enne muscular dystrophy [DMD, 13] and other myopathies such as
dermatomyositis [2], but the underlyingmechanisms remained unclear.
In peripheral macrophages, vagus-released ACh triggers an anti-
inﬂammatory signal-transduction pathway. This effect is initiated by
activation of the macrophage α7 nicotinic receptor (AChRα7) and
culminating in suppression of NF- B-dependent transcription of pro-
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NF- B nuclear localization by phosphorylated I- B and activation of the
JAK2-STAT3 pathway to disrupt the DNA binding activity of NF- B [14].
More recently this so-called cholinergic anti-inﬂammatory pathway
[14] was demonstrated in a mouse model of DMD, where nicotine ad-
ministration reduced skeletal muscle inﬂammation by suppressing the
expression of cytokine production in inﬁltrating macrophages [15].
Yet, direct cholinergic suppression of inﬂammation in themuscle tissue
itself was not yet addressed.
Cholinergic signaling often promotes survival. For example, in
small cell lung carcinoma and pig retinal ganglion cells, cholinergic
activation of either muscarinic [7] or nicotinic [16] receptors triggers
phosphatidylinositol 3-kinase-mediated phosphorylation of AKT,
resulting in the concomitant activation of proliferative transcription
factors and inhibition of pro-apoptotic proteins. Additionally, in the de-
veloping rat hippocampus, cholinergic signaling promotes survival by
enhancing expression of neurotrophic factors [17]. In muscles, inﬂam-
mation is often accompanied by apoptosis, as was demonstrated in
DMD mouse models and human patients ([e.g. in DMD mouse models
and human patients, 18]), and in muscle injuries [1,19,20]. However,
it remains unknown if cholinergic activation is also coupled to inﬂam-
mation and apoptosis, and if so, what are the underlying mechanisms.
Many apoptosis-related genes undergo alternative splicing that yields
variants with inverse functions (e.g. the prevalent, long anti-apoptotic
Bcl-X and Mcl-1 variants and their rare, short pro-apoptotic variants
[21]). Similarly, various genes in the pro-inﬂammatory pathway regulat-
ed by NF- B undergo alternative splicing, which may negatively regulate
NF- B and reverse its effect [22]. Alternative mRNA processing is usually
regulated by extra-cellular signals, and cholinergic signals are among
them. For example, activation of brain muscarinic receptors by pilocar-
pine initiates alternative promoter choices in the BDNF gene and alterna-
tive splicing of many other transcripts (e.g. AChE, NMDAR1) [23,24].
Likewise, nicotinic stimulation in PC12 cells induces the expression of
mRNA-binding proteins that bind tyrosine-hydroxylase and increases
its stability [25], pointing at acquired changes in RNA processing as a pu-
tative mechanism downstream to cholinergic signaling.
A possible link between mRNA processing, inﬂammation and cell
survival is the RNA binding protein Tristetraprolin (TTP). TTP is a
zinc ﬁnger protein that binds AU-rich elements (ARE) in the 3′
untranslated region (UTR) of its target transcripts, and promotes
their degradation by recruiting proteins involved in de-adenylation
(e.g. xrn1) [26], de-capping (e.g. DCP2) [27], or microRNA (miR)-de-
pendent degradation [28]. TTP-null mice develop a complex disorder
that includes cachexia, myeloid hyperplasia, and joint and skin inﬂam-
mation. Mice deﬁcient in both TTP and TNF receptor 1 are protected
from this disorder, suggesting that it is TNF-mediated [29]. Several
other cytokine transcripts that contain AREs are regulated by TTP,
such as IL-6 [30] and IL-2 [31]. Additionally, TTP regulates the mRNA
levels of transcripts involved in cell proliferation andmetastasis, for ex-
ample in breast cancer processes and in human lung cancer cells
[32,33]. TTP also binds the ARE of the apoptosis regulator, cIAP2 and
promotes its degradation [34]. A recent article demonstrated that TTP
mediates the cholinergic anti-inﬂammatory effect inmacrophages [35].
Based on the central role of ACh in the NMJ on the one hand, and its
involvement in prominent cellular processes implicated in muscular
disease on the other hand, we set out to investigate cholinergic-
mediated changes inmRNAprocessing in skeletalmuscles, and challenge
their importance in regulating cell death and inﬂammatory responses in
muscle cells.
2. Materials and methods
2.1. Animal experiments
Groups of 4–6 male FVB/N mice were I.V. injected with 550 μg/kg
Paraoxon (PO, 0.83× LD50, Sigma, St. Louis, MO, USA), 1000 U puriﬁedrecombinant AChE-R [36] or a combination of both. Control mice were
injected with an equivalent volume (100 μl) of sterile PBS. Where
noted, mice were injected with 400 μg/kg nicotine (Sigma) or PBS. No
additional supportive measures were provided. At the indicated time
points, micewere sacriﬁced and solid tissue/whole bloodwas collected.
Muscle tissues were immediately frozen on dry ice and subsequently
stored at−80 °C until further use. Serumwas prepared by centrifuging
whole blood (15 min, 3000×g, 4 °C). Supernatants were removed and
stored at −80 °C. All animal experiments were performed with the
approval of the animal care and use committees at either Arizona State
University or the Hebrew University of Jerusalem.
2.2. Cell culture
C2C12 cells were obtained from the American Type Culture Collec-
tion (ATCC, Manassas, VA). They were grown in Dulbecco's modiﬁed
Eagle's medium (+10% fetal calf serum), at 37 °C, 5% CO2 in humidiﬁed
chambers, and passaged every three to four days by trypsinization. To
induce differentiation into myotubes, growth medium was replaced
on Day 2, 4 and 6 with DMEM (+2% horse serum), and cells were
used on Day 7 [37]. Differentiated cells were treated with 0.01–
100 μM nicotine, 1.5 ng/ml–1.5 μg/ml LPS (Sigma), or a combination
of both. For Mcl-1 protein quantiﬁcation, cells were treated with 5 μM
PO. Where indicated, Day 7 differentiated C2C12 myotube cultures
were incubated in the presence of 50 μg/ml α-amanitin (Calbiochem,
La-Jolla, CA) for the indicated duration.
2.2.1. Generation of shTTP cell line
To disrupt TTP expression we employed ‘Block-it pol-II miR RNAi ex-
pression vectors’ (Invitrogen, Carlsbad, CA, USA) speciﬁcally designed to
target mouse TTP transcripts. These plasmids also included the gene for
emerald GFP and blasticidin-resistance gene. A day after being sown in
6-well plates, undifferentiated C2C12 myoblasts were transfected with
one of the three TTP or scrambled shRNAs (miR-like) encoding vectors,
using lipofectamine-2000 reagent (Invitrogen). From Day 3 (when
~40% of the cells were observed to express emerald GFP) through Day
13, cells were grown in a medium containing 6 μg/ml blasticidin
(Sigma) for selection. Following screening, we selected for further anal-
ysis the cell line that expressed the lowest levels of TTP mRNA and pro-
tein (shTTP). A cell line expressing high levels of the scrambledmiR was
similarly selected (shCTL). Whenever needed, frozen shTTP and shCTL
cells were thawed, grown and differentiated inmedium containing blas-
ticidin. Unless stated otherwise, all cell culture materials were obtained
from Biological Industries, Israel.
2.3. RNA extraction, quantitative RT-PCR and 3′RACE (rapid ampliﬁcation
of cDNA 3′ ends)
RNA was extracted using the RNeasy Minikit (Qiagen, Hilden,
Germany) or the RNAqueous system with DNA-free treatment per
manufacturer's instructions (Ambion, Austin, TX). Total RNA was re-
verse transcribed using random primers and Improm-II reverse tran-
scriptase (Promega, Madison, WI, USA) or using the RetroScript system
per manufacturer's instructions (Ambion).
Real-time quantitative RT-PCR (qRT) was performed on an ABI
Prism 7900 Sequence Detector (Applied Biosystems, CA, USA) accord-
ing to the manufacturer's instructions. Each sample was tested 3
times. Deviant replicates were omitted if SD>0.15 cycles. Data were
normalized to 18S rRNA levels (muscle) or to a combined factor of
Gapdh and α-tubulin levels. See Supplementary Table 1 for complete
list of primers.
For 3′RACE, total RNA (400 ng) was similarly reverse transcribed
using the 3′RACE-RT primer (Supplementary Table 1). cDNA frag-
ments corresponding to Mcl-1 transcripts were PCR-ampliﬁed using
Ex-Taq DNA polymerase (Takara, Shiga, Japan), the speciﬁc 3′RACE-
Mcl-I and the universal 3′RACE-uni primers (Supplementary Table
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45 s; 64 °C – 45 s; 72 °C – 2.5 min]. PCR products were analyzed
using 1% agarose gel.
2.4. Cytokine and transcription factor ELISAs
Secreted IL-6 and CCL2 protein in conditioned medium from
C2C12 cells (collected over a 24 h period) was assayed by ELISA
using anti-murine IL6 and anti-murine CCL2 Abs, HRP-linked second-
ary Abs and 3,5,3′,5′-tetramethylbenzidine as a substrate according to
the manufacturer's instruction (Ready-set-go! Kits, eBioscience, San-
Diego, CA). Absorption (450 nm) was measured with SpectraMax
340PC plate reader (Molecular Devices, Sunnyvale, CA).
Activity of the transcription factor NF- B and AP-1 was assayed
using the TransAM™ NFκB (p65) and TransAM™ AP-1 (c-fos) Tran-
scription Factor ELISA kits (Active Motif, Carlsbad, CA, USA) according
to the manufacturer's instructions.
2.5. Immunoblotting
Total proteins from C2C12 cells that were lysed in SDS sample
buffer were resolved by SDS-PAGE on 10% gels (BioRad, Hercules,
CA) and blotted onto nitrocellulose membranes. Membranes were
blocked with either 5% BSA or 5% skim milk, and then probed over-
night at 4 °C with a rabbit polyclonal antiserum raised against the
C-terminus of mouse TTP (SAK21B, 1:2500, a kind gift of Prof. Clark,
Imperial college London, UK), rabbit polyclonal Mcl-1 Ab (1:800, Bio-
legend, San Diego, CA) or mouse monoclonal alpha-tubulin Ab
(1:2000, Santa Cruz biotechnology, Santa Cruz, CA). Speciﬁcally-
bound primary Abs were probed by incubation (1 h, room tempera-
ture) with HRP-conjugated secondary Abs (1:5000, Jackson Laborato-
ries, West Grove, PA) and detected by enhanced chemiluminescence
reagents (EZ-ECL, Biological industries, Israel). The TTP Ab detects
two bands, probably reﬂecting different phosphorylation states
[38,39]. TTP quantiﬁcation included both bands together. Relative
amounts of TTP and Mcl-1 proteins in each sample were determined
by quantifying each band's densitometry and normalizing it to the
relative amount of alpha-tubulin in the same sample.
2.6. Bioinformatics analysis of Mcl-1 3′-UTR
Polyadenylation sites in the mouse and human Mcl-1 genes were
identiﬁed using the PolyA_DB database for mammalian mRNA polyade-
nylation [http://polya.umdnj.edu/PolyA_DB1/about.php, 40] and the Al-
ternative Transcript Diversity database [http://www.ebi.ac.uk/atd/, 41].
2.7. Microarray experiments
Microarray design, RNA preparation and hybridization, scanning,
basic analysis and normalization were performed according to [42,43].
Brieﬂy, each microarray slide was hybridized with two distinct ampli-
ﬁed, labeled muscle RNA samples, each composed from a pool of 4–6
mice. The resultant values are the relative ratio between hybridization
signals, so data is always relative in nature rather than absolute, based
on the “reference design” [44]. Supplementary Table 2 summarizes
the different comparisons tested by the microarrays. To exclude dye-
speciﬁc labeling differences, we performed dye-swapping tests [45].
Duplicate slides were used for each speciﬁc sample/label combination,
so that each comparison includes four SpliceChip slides. Data ﬁltration,
normalization and analysis were performed with the Imagene software
(Biodiscovery, CA, USA) and custom written Matlab programs.
2.7.1. Statistical analysis of microarray data
2.7.1.1. identifying signiﬁcantly changed transcripts and groups of tran-
scripts. Two approaches were used to identify transcripts and groupsof transcripts whose expression levels were signiﬁcantly altered
[46]. Following the discrete approach, we ﬁrst identiﬁed changed
transcripts as those that were changed by more than 1.5-fold follow-
ing treatment. Using the continuous approach, we searched for func-
tional categories of transcripts that were differentially regulated as
compared to all other transcripts on the SpliceChip. To this end, the
cumulative distributions of the transcripts in each functional group
were compared to those of the total population of transcripts on the
chip, testing for signiﬁcant differences between those two distribu-
tions by the two-sided Kolmogorov–Smirnov (KS) test [46].
2.7.1.2. Global correlations between treatments, time points and experi-
mental systems. We calculated correlations between the changes in
expression of all transcripts following the same treatment in different
time points, and following different treatments at the same time
points. Additionally, we compared the changes induced by AChE-R in-
jection in muscles, to those induced by over-expression of the human
AChE-R protein in murine P19 cells. These cells are embryonic carcino-
ma cells which upon inductionwith retinoic acid differentiate into neu-
rons. We used those cells at differentiation on Day 5, at which they are
deﬁned as ‘neuronal precursors’ according to their morphology and
gene expression [47]. All correlations were tested by Pearson's correla-
tion test and represented by scatter plots and regression lines.
2.7.1.3. Correlations between mRNA processing factors and target genes.
The expression changes of each apoptosis-related transcript in all 6
experimental comparisons (see Supplementary Table 2) were corre-
lated using Pearson's correlation tests with parallel changes in each
of the mRNA processing factors. ‘target-factor’ pairs that showed sig-
niﬁcant correlations (pb0.0001) were identiﬁed and presented in
correlation matrices.
2.8. Other statistical analysis
Student's t-test was used for testing PO and nicotine effects on
mRNA expression levels of Mcl-1, TTP, TNFα, IL-6, CCL2 and CXCL1
in muscles. 1-sample t-test was used for assessing TTP and IL-6
mRNA, and TTP protein expression in shTTP cells. Mann–Whitney
test was used for quantiﬁcation of TTP mRNA and protein, and Mcl-
1 protein in differentiated C2C12 cells. A two-way ANOVA followed
by Bonferroni post-hoc analysis was used for comparing CCL2 and
CXCL1 mRNA and secreted proteins following treatments with differ-
ent concentrations of nicotine and LPS in C2C12 cells, and for assessing
nicotine effects on NF- B and AP-1 transcription activities in those
cells.
All bars represents mean values, and error bars delineate standard
error of the mean (S.E.M). Wherever bars represent fold change over
control values, 1 stands for no change.
3. Results
Cholinergic stimulation can alter mRNA processing [24,25,48], im-
prove cell viability [7,49], and regulate inﬂammation [5,6] in different
tissues. Since muscle ﬁbers are activated by ACh, we speculated that
ACh regulates cell death and inﬂammation in this tissue as well, and
that TTP can be a mediator of this regulation.
3.1. Nicotinic stimulation regulates pro-inﬂammatory transcripts inmuscle
cells
In cells of the immune system, cholinergic stimulation regulates
inﬂammation through nicotinic receptors [5]. Thus, we set out to
ﬁnd if nicotinic stimulation can induce an anti-inﬂammatory re-
sponse in muscles. We produced nicotinic stimulation in the muscle
and tested whether it decreases the expression of pro-inﬂammatory
cytokines. We observed pronounced reduction in the mRNA levels
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4 h after nicotine injection (pb0.05, Fig. 1A). These chemokine tran-
scripts were already shown to be regulated by ACh signaling in non-
muscle tissues [50,51], and are known targets of the mRNA binding
protein TTP [30,52]. Similarly, IL-6 and TNF-α transcript levels were
reduced 2 h after exposure to a sub-lethal dose of the AChE inhibitor,
Paraoxon (PO), that also generates enhanced cholinergic transmission
in the NMJ (pb0.05, Supplementary Fig. 1A).
To rule out contribution of non-muscle cells to the effects observed
above, we turned to an in-vitro model of skeletal muscle cells. Congru-
ent with the literature and our in-vivo experiments, CCL2 mRNA levels
were induced by LPS exposure (reaching 11-fold increase over control
1 h after treatment), but this induction was attenuated by combined
treatment with nicotine (pb0.001, Fig. 1B). Nicotine treatment alone
reduced basal CCL2 mRNA levels within 1 h after treatment (pb0.05,
Fig. 1B). In contrast, CXCL1 mRNA levels were only modestly inducedA
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Fig. 1. The cholinergic anti-inﬂammatory effect in muscles. (A) Nicotine reduces CCL2
and CXCL1 mRNA expression in skeletal muscles, 4 h after treatment (n=4–6 per
group, *pb0.05, Student's t-test). (B) Nicotine (50 μM) attenuates LPS-induced expres-
sion of CCL2 transcripts in C2C12 cells (n=4 per group, *pb0.05, **pb0.001 in compar-
ison to no treatment, #pb0.001 in comparison to 100 ng/ml LPS alone) please note the
different scales for nicotine treatment alone comparing with LPS treatments. (C) In
C2C12 cells, secreted CCL2 protein is accumulated over time, but reduced by nicotine
in a dose-dependent manner (n=4 per group, *pb0.05, #pb0.001, in comparison to
no nicotine) (D) LPS-induced CCL2 secretion is also suppressed by nicotine, 48 h after
treatment (n=4 per group, #pb0.001 in comparison to no nicotine) (E) Basal CXCL1
secretion in C2C12 cells is attenuated by nicotine (n=4 per group, *pb0.05,
$pb0.01, #pb0.001 in comparison to no nicotine). (F) Nicotine does not attenuate
15 ng/ml LPS-induced CXCL1 secretion, 48 h after treatment (n=4 per group,
$pb0.01, #pb0.001 in comparison to no nicotine). All analyses in panels C–F were sub-
jected to Bonferroni post-hoc correction after a two-way ANOVA.by LPS (reaching 2-fold increase 4 h after treatment (pb0.05, Supple-
mentary Fig. 2)) and the combined treatment with nicotine did not at-
tenuate this affect. Interestingly, nicotine treatment alone induced,
rather than reduced, CXCL1 expression 1 and 4 h after treatment
(pb0.001). At the protein level, basal CCL2 secretion was suppressed
in a dose-dependent and time-dependent manner by nicotine. At 48 h
post-treatment, 0.01 μM nicotine reduced secreted CCL2 by 20.6%
(pb0.05), reaching 68.1% suppression at 100 μM nicotine (pb0.001,
Fig. 1C). Exposure to 1.5 μg/ml of the exogenous inﬂammatory inducer,
LPS, induced 20-fold more prominent release of CCL2, which was like-
wise subjected to nicotine-mediated suppression (pb0.001, Fig. 1D).
Similar, but less pronounced, nicotine-mediated suppression was seen
for CXCL1 secretion, where nicotine at a concentration of 10 μM and
more was required for suppression of basal secretion (pb0.05, Fig. 1E).
48 h after treatment, 100 μM nicotine reduced CXCL1 secretion by 30%.
Interestingly, when cells were treated with LPS in a concentration re-
quired to enhance CXCL1 secretion (15 ng/ml), combined treatment
with nicotine did not attenuate this induction (Fig. 1F). However, this
LPS concentration is still much lower than the one used for demonstrat-
ing the attenuation of LPS-induced CCL2 secretion (1.5 μg/ml). Thus, fur-
ther experiments are needed to determine whether nicotine can also
suppress CXCL1 secretion after exposure to higher concentrations of LPS.
3.2. Tristetraprolin mediates the attenuating effect of nicotine in muscle
cells
Next, we tested whether TTP can be the mediator of this choliner-
gic anti-inﬂammatory response in muscle cells. In muscles of treated
mice, both nicotine and PO rapidly induced TTP mRNA expression
(pb0.05, Fig. 2A and Supplementary Fig. 1B). In C2C12 cells, nicotine
induced TTP mRNA levels yet more prominently (pb0.05, Fig. 2B and
Supplementary Fig. 3), suggesting that cholinergic effect on TTP tran-
scription occurs in muscle cells themselves and not only in macro-
phages as was previously suggested [15,35]. Importantly, we cannot
completely rule out the possibility that nicotine and PO induce TTP
expression in a mechanism independent of cholinergic receptors.
However, the similar effects of nicotine, which is a direct cholinergic
agonist and PO, which indirectly activate cholinergic signaling by
inhibiting AChE, strongly propose a direct cholinergic involvement.
TTP transcription induction led to a less pronounced, yet signiﬁcant, in-
crease in TTP protein levels (pb0.05, Fig. 2C). As in other cell types,
treating C2C12 cells for 4 h with 10 μM nicotine treatment suppressed
the activation of NF- B, and 0.5 h of 1 μMnicotine treatment suppressed
AP-1 (pb0.05, Fig. 2D and E).
TTP induction could hence be either an essential step in the cho-
linergic anti-inﬂammatory pathway in muscles, or a secondary out-
come of the suppression of immunologically-relevant transcription
factors such as NF-kB and AP-1. To distinguish between these possibili-
ties, we stably transformed C2C12 cells with an shRNA agent directed
against the murine TTP transcript (shTTP cells). The shTTP cells express
considerably lower levels of both TTPmRNA and protein in comparison
to control cells transformed with scrambled shRNA (shCTL, pb0.05,
Supplementary Fig. 4). Correspondingly, shTTP cells express higher
levels than control cells of the TTP target, IL-6, likely reﬂecting reduced
TTP-mediated degradation of IL-6 transcripts (pb0.005, Supplementary
Fig. 4).
Then, we examined the effect of nicotine treatment and LPS expo-
sure on pro-inﬂammatory transcripts in shTTP cells. We chose one cy-
tokine, IL-6, and one chemokine, CCL2, as representative transcripts.
In basal conditions, nicotine signiﬁcantly reduced IL-6 and CCL2 ex-
pression in control, but not in shTTP cells (pb0.05, Fig. 2F), implying
that normal levels of TTP are essential for the immunosuppressive ef-
fect of nicotinic stimulation. Importantly, nicotine treatment did not
signiﬁcantly increase IL-6 and CCL2 expression in shTTP cells. To our
surprise, we failed to induce CCL2 and IL-6 expression in shTTP cells
exposed to LPS, unlike shCTL cells which presented a robust response
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Fig. 2. TTP is essential for cholinergic regulation over muscle inﬂammation. (A) RNA was extracted from quadriceps muscle of mice treated with nicotine (400 μg/kg) in the indi-
cated time points and resulting qRT-PCR demonstrated rapid induction of TTP mRNA (n=4–6 per group, *pb0.05, Student's t-test). (B) Nicotine strongly induces TTP mRNA ex-
pression in C2C12 cells. Shown is a representative experiment, see a similar experiment in Supplementary Fig. 3. (n=3 per group, *pb0.05, MW test). (C) Nicotine treatment
also leads to TTP protein increase in C2C12 cells. LPS-treated macrophage cell line (RAW-LPS) served as positive control, TTP amounts were normalized to alpha-tubulin (tub) levels
at the same samples (n=3 per group, pb0.05, MW test, Tub=tubulin). (D, E) nicotine-treated C2C12 cells show reduced activity of NF- B and AP-1 compared to non-treated cells
(n=4 per group, *pb0.05; #pb0.001, Bonferroni post hoc analysis after a two-way ANOVA). (F) TTP knockdown impairs both the anti-inﬂammatory response to nicotine and pro-
inﬂammatory response to LPS in C2C12 cells. C2C12 cells were stably transfected with either scrambled shRNA (shCTL) or TTP-targeting shRNA (shTTP). These cells were treated
with nicotine (50 μM), LPS (500 ng/ml) or a combination of both. shCTL, but not shTTP cells showed reduction in CCL2 and IL-6 mRNA expression in response to nicotine treatment.
Furthermore, shTTP cells did not increase CCL2 and IL-6 in response to LPS, and nicotine pre-treatment altered the response to LPS (attenuated CCL2, but potentiated IL-6 expres-
sion) in shCTL but not shTTP cells (n=5–6 per group, *pb0.05, **pb0.001 in comparison to no treatment in the same cell line; #pb0.001 in comparison to shCTL cells; $pb0.05, $
$pb0.001 in comparison to LPS treatment alone in the same cell line, Bonferroni post-hoc analysis after a two-way ANOVA).
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induced CCL2 (pb0.05) and IL-6 (pb0.001) mRNA expression in
shCTL, but not in shTTP cells. Interestingly, nicotine further enhanced
IL-6 expression in shCTL cells, and not attenuated it. Thus, in addition
to its above-demonstrated role in nicotine-mediated immunosup-
pression, TTP expression is important for cholinergic-independent,
LPS-related cytokines expression.
3.3. Cholinergic signaling in the murine NMJ regulates the expression of
mRNA processing factors and their apoptotic-related targets
Next, we aimed to test cholinergic regulation over muscle RNA pro-
cessing and apoptosis, and the possible role of TTP in such processes. To
simulate cholinergic changes in the NMJ, we injected FVB/N mice with
either PO (550 μg/kg, 0.83× LD50), recombinant AChE-R (the usually
rare, soluble AChE variant), which should reduce cholinergic signaling
and elevate inﬂammation, or a combination of both. We extracted
RNA from the quadriceps muscles two and six hours after treatment
and used an homemade DNAmicroarray [42] to screen for differentially
regulated mRNA processing factors, and their target genes that are in-
volved in cell death and undergo alternative mRNA processing. Wefurther quantiﬁed the expression of 13 transcripts represented on the
array in all six experimental situations (treatment×time) by qRT-PCR
and successfully validated 77% of the array results.
PO operates both as an anti-AChE and as a DNA alkylating agent.
The consequent hyper-cholinergic signaling induces a feedback re-
sponse of AChE over-production [53,54]. Nevertheless, when AChE-
R is injected together with PO it serves as a scavenger for the PO mol-
ecules [36] and attenuates or even prevents some of the predicted
PO-induced changes. Therefore, we surmised that AChE-R injection
in muscles should induce a subset of those transcript modiﬁcations
caused by PO, and that the difference between the effects of AChE-R
and PO treatments should largely reﬂect those consequences of PO
exposure which are non-cholinergic. Additionally, earlier work dem-
onstrated that the motor effects of PO and/or AChE-R injections at the
indicated doses are rapid and transient [36] and we expected the mo-
lecular changes to follow a similar kinetics. Correspondingly, injection
of PO, recombinant AChE-R or a combination of both altered the ex-
pression levels of mRNA processing and apoptosis-related transcripts
in comparison to saline injection. By two hours post-treatment, 11,
9.8 and 9% of the tested transcripts were changed by over 1.5-fold,
and after 6 h, the percentages of changed transcripts dropped to 5.7,
373B.C. Geyer et al. / Biochimica et Biophysica Acta 1823 (2012) 368–3785.3 and 3.3, respectively. Summation of changes across all transcripts
in each experimental condition also indicated more changes two
hours after treatment, with PO treatment alone causing more changes
than the other treatments. (n=4–6 per group, Fig. 3A). Thus, the timing
of expression changes in mRNA processing factors and apoptosis-
related transcripts correspond to the behavioral changes. Interestingly,-
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ticed positive correlation between changes induced by AChE-R or PO
(pb0.001, Pearson's correlation test, Fig. 3C), suggesting that AChE
over-production caused part of the PO-induced changes. However, co-
injected AChE-R inverted the PO-mediated effect on mRNA processing
factors (pb0.001, Pearson's correlation test, Fig. 3C), in agreement
with the expected effects on cholinergic transmission.
We also tested whether the cholinergic-mediated changes in the
expression of mRNA processing factors were limited to speciﬁc sub-
groups of these factors, by comparing the changes in each functional
group to the global changes in each experimental condition. Using
the KS test, we could not identify any signiﬁcantly changed category, in-
dicating that the changes are transcript-speciﬁc and cannot be grouped
according to speciﬁc functions in the mRNA processing machinery.
To test whether the cholinergic-mediated changes are speciﬁc to
skeletal muscles, we compared the AChE-R-induced changes to
those observed in neuronal precursor cell cultures (semi-differentiat-
ed P19 cells) transfected with the AChE-R expressing vector [42]. We
noticed a signiﬁcant correlation between the changes occurring six
(pb0.001), but not two (p>0.05) hours after AChE-R injection to
the NMJ to those observed in neuronal precursors 24 h after AChE-R
transfection (Pearson's correlation test, Fig. 3D), indicating that to
some extent, cholinergic stimulation exerts global changes in mRNA
processing factors. Speciﬁcally, when setting the threshold for ‘chan-
ged transcript’ as 1.5-fold change, four transcripts were detected as
‘changed’ in both systems; the splicing factor, sf3a1, was reduced by
excessive levels of AChE-R both in muscles and neuronal precursors,
and the long variant of the pro-apoptotic transcript, Fas, was signiﬁ-
cantly induced in the two systems. Additionally, the SR protein,
SRp55, was reduced two hours after AChE-R injection in the muscles
and in the neuronal precursors, and the transcript encoding the RNA-
binding protein, Rnpc2, was inversely affected in the two systems
(Fig. 3D).
Next, we examined changes in mRNA processing factors across the
experimental treatments and searched for corresponding changes in
apoptosis-related transcripts known to undergo alternative mRNA
processing that modiﬁes their function, possibly reﬂecting functional
relationships between the two. Out of 8100 valid ‘mRNA processing
factor-apoptotic target’ pairs, 13 were signiﬁcantly correlated with
pb0.0001 (Supplementary Table 3). Within this subset of correlated
pairs, we revealed complex relationships between cholinergic changes
and apoptotic transcripts. For example, two hours after injection with
either AChE-R or PO, the expression of the SR protein kinase, Clk1,
was increased. Additionally, Clk1 was negatively correlated with the
pro-apoptotic transcript Fas-long (p=0.0086), and positively correlated
with the anti-apoptotic transcript, Bcl-X-com (p=0.0048), suggesting
that enhanced cholinergic signaling induced a Clk1-mediated anti-
apoptotic effect. However, both AChE-R and PO injections increased
Clk3 expression, and this factor was positively correlated with caspase-
6 (p=0.01) but negatively correlated with expression of the anti-
apoptotic protein Mcl-1 (p=0.0026), suggesting a pro-apoptotic effect
in this case. Validating this experimental investigation, we noticed a
strong positive correlation between the expression of the alternative
splicing factor, plrg1 [55], and the pro-apoptotic transcript bax-alpha
(p=0.005). Earlier study already identiﬁed plrg1 in regulation of apo-
ptosis, although it served as an anti-apoptotic regulator of p53-
depdenent apoptosis [56] (Supplementary Fig. 5).
3.4. Cholinergic imbalances in the NMJ alter polyA site selection in the
Mcl-1 gene
To obtain an in-depth view of one of the changes, we selected for
further investigation the anti-apoptotic gene, Mcl-1, which prevents
apoptosis by creating heterodimers with pro-apoptotic Bcl-2 proteins
such as BAK and BAX, preventing their actions [57]. Both AChE-R and
PO treatments caused suppression of Mcl-1, and the combinedtreatment inverted this effect (Fig. 3E). Primers targeting the extreme
3′ end of the transcript conﬁrmed these results. Importantly, primers
targeting a more 5′ part of the transcript did not show such changes,
suggesting a 3′-speciﬁc effect (pb0.001, Fig. 4A). In-silica analysis of
the murine Mcl-1 genomic region revealed three potential alternative
polyadeylation sites which are conserved in humans and are assumed
to yield three distinct transcripts that share an identical coding region
but are different in the length of their 3′ UTR (Fig. 4B). These “short”
(S), “intermediate” (I) and “long” (L) UTR-containing species are all
present in mouse skeletal muscle, as demonstrated by 3′RACE
(Fig. 4C). In conclusion, cholinergic changes modulated Mcl-1 polya-
denylation site selection in skeletal muscles.
Since this is the ﬁrst experimental demonstration of selective regu-
lation over the 3′ region of Mcl-1, we explored possible differences be-
tween the variants. In differentiated C2C12 murine myotubes exposed
to the RNA polymerase II inhibitor, α-amanitin, this revealed that
Mcl-1 transcripts with the long-3′-UTR were more rapidly degraded
compared with transcripts with short-3′-UTR (Fig. 4D). Also, western
blotting ofMcl-1 usually yields two distinct bands, which result from ei-
ther alternative splicing [58] or post-translational modiﬁcation [59],
and PO treatment elevated the expression of these two Mcl-1 forms
(pb0.05, Fig. 4E). Together, these ﬁndings suggest that PO treatment re-
duces the selection of the less stable long variant, leading to increased
selection of the other,more stable transcriptswhich results in enhanced
accumulation of the anti-apoptotic Mcl-1 protein. Supporting this con-
clusion, theMcl-1 3′UTR includes no less than eight AUUUARNAdesta-
bilizing sequences (ARE pentamers). Of these, one was in the common
3′-UTR, four in the region common to the long and intermediate variant,
and the remaining three were in the unique long UTR. Thus, the long
variant contains as many as eight ARE pentamers. Furthermore, one of
the pentamers unique to the long variant is actually a part of the octa-
mer UUAUUUAU, similar to the ‘classic’ UUAUUUAUU nonamer identi-
ﬁed as a strong TTP binding motif (Fig. 4B). The presence of several
pentamers and one octamer points at Mcl-1 long variant as a potential
TTP target [60–62].
4. Discussion
We found that nicotinic stimulation suppressed the expression of
pro-inﬂammatory cytokines in mouse muscle tissues and myotube
cell culture. This suppression was accompanied by enhanced expres-
sion of the 3′ mRNA processing factor, TTP, and was abolished in cells
with ablated TTP expression. High throughput screening revealed
that cholinergic changes in the NMJ rapidly altered muscle transcript
levels of several mRNA processing factors, with most of these changes
being reversible within 6 h. Interestingly, some of the changes were
correlated with alterations in apoptosis-related transcript levels. Spe-
ciﬁcally, injection of the AChE inhibitor, PO, modulated the 3′ mRNA
processing pattern of the anti-apoptotic gene, Mcl-1, switching from
selection of the most distant polyadenylation site and corresponding-
ly suppressing the production of the long and less stable Mcl-1 mRNA
variant, which carries eight ARE pentamers. These ﬁndings and the
inverse correlation between TTP and the long Mcl-1 variant are com-
patible with the hypothesis that TTP mediates cholinergic control
over inﬂammation and apoptosis in muscles (Fig. 5).
In macrophages, cholinergic stimulation regulates inﬂammation
through a speciﬁc subtype of nicotinic receptors, namely AChRα7 [5].
Traditionally, it is believed that the NMJ of adult mammals express
other subtypes of nicotinic receptors. However, AChRα7 expression
was detected in chick and rat skeletal muscle during development and
denervation [63]. Moreover, immunohistochemistry in human tissues
revealed moderate AChRα7 staining in skeletal muscles (http://www.
proteinatlas.org/ENSG00000175344/normal/skeletal+muscle). Addi-
tionally, it is possible that the nicotine and/or PO treatments by them-
selves alter the composition of nicotinic receptors in the NMJ. In any
case, we cannot rule out that the inducing effects of nicotine and PO
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Fig. 5. TTP is a potential mediator for the cholinergic effect on apoptosis and inﬂamma-
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otinic receptors by ACh or nicotine (Nic). Alternatively, it can result from inhibition of
the ACh-hydrolyzing enzyme, AChE with Paraoxon (PO) or other inhibitors. In turn,
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long variant of Mcl-1 by inducing their negative regulator, TTP. This can result in re-
duced inﬂammation and apoptosis, respectively.
375B.C. Geyer et al. / Biochimica et Biophysica Acta 1823 (2012) 368–378on TTP expression are mediated by non-α7 nicotinic receptors in mus-
cle cells, and the question of the identity of the speciﬁc nicotinic recep-
tors involved in anti-inﬂammatory response in muscles is yet to be
answered. Furthermore, the speciﬁc mechanism by which nicotinic re-
ceptors convey the TTP-inducing effect is still unclear.
Investigating the effect of nicotinic stimulation on pro-inﬂammatory
cytokines involved treating C2C12 cells with nicotine and LPS. Nicotinereduced basal CXCL1 secretion, and both basal and inﬂammation-
induced secretion of CCL2. Thus, it is possible that impairment of nico-
tinic activation of muscle cells, as occurs in myasthenia gravis [64] or
muscle injuries [65], chronically exposes muscle cells to high levels of
chemokines while disrupting their ability to suppress inﬂammatory in-
duction under secondary insults. This may explain the development of
chronic inﬂammation and enhanced cell death in these conditions
[1,13]. In agreement with that, exposure to the ACh receptor antibody
in a rat model of myasthenia gravis was found to increase CCL2 expres-
sion in skeletal muscle cells [66]. In turn, CCL2 attracts T-cells and
monocytes into the muscle, encouraging enhanced cytokines expres-
sion and exacerbates the pathology [67]. Indeed, increased expression
of both CCL2 and CXCL1 in endothelial cells and in inﬁltrating immune
cells within muscle tissue that is observed in several myopathies [68]
may be attributed to the impaired nicotinic signaling. Additionally,
CCL2 has a central role in the communication between adipose tissue
and skeletal muscles [69]. CCL2 is over-expressed in obese rodents
and people, and its binding to its receptor, CCR2, can trigger insulin re-
sistance in skeletal muscles, which is part of the ‘metabolic syndrome’
and can precede type 2 diabetes [70]. Thus, cholinergic control over
CCL2 expression in muscles further suggest that cholinergic changes
might also play a prominent role in the development of insulin resis-
tance inmuscles. Indeed, serumbutyrylcholinesterase levelswere asso-
ciated with indicators of the metabolic syndrome such as abdominal
obesity and insulin concentration in the plasma [71].
Nicotinic control over IL-6 expression, as was demonstrated in
nicotine-treated C2C12 cells, suggests that normal cholinergic signal-
ing in the NMJ is important also for controlling exercise-induced ef-
fects on systemic inﬂammation and metabolism, which are largely
mediated by muscle IL-6 secretion [12]. Moreover, it is possible that
exercise-induced changes in peripheral AChE [72] are involved in
the regulation of muscle IL-6 secretion during physical activity.
Our results demonstrated nicotine-mediated suppression of NF-κB
and AP-1 activity, as was already shown in other cell types [73]. How-
ever, this suppression could not fully account for the suppressive ef-
fect of nicotine on pro-inﬂammatory transcripts, since cells with
ablated TTP expression did not show this suppressive effect. Thus,
TTP induction and NF-κB/AP-1 suppression may jointly act to reduce
pro-inﬂammatory transcript levels. However, TTP interrupts NF-κB
translocation and transcriptional activity [74,75], whereas NF-κB
may be involved in TTP expression [76]. Therefore, nicotinic stimula-
tion affecting one of these factors would inﬂuence the other as well.
Traditionally, TTP is regarded as a negative regulator of inﬂamma-
tion, as it suppresses several pro-inﬂammatory cytokines such as
TNFα [29] and IL-6 [30], and since it negatively regulates the activity
376 B.C. Geyer et al. / Biochimica et Biophysica Acta 1823 (2012) 368–378of NF-κB [74,75]. However, its effect on inﬂammation appears to be
more complex, as it also promotes the degradation of the anti-
inﬂammatory cytokine IL-10 [62] and of its own transcript [77].
Moreover, TTP induction is bi-phasic; its expression is induced by
the p38-MAPK pathway, but proteins of this pathway also phosphor-
ylate TTP, holding it in a latent state. Only when the activity in this
pathway is diminished, TTP is de-phosphorylated and becomes active
[77,78]. Therefore, inﬂammatory stimuli, such as LPS, trigger the ex-
pression of pro-inﬂammatory genes but at the same time trigger
TTP expression as a ‘preparation of the antidote’ for preventing
chronic inﬂammation. In our study, TTP-deﬁcient C2C12 cells failed
to response to LPS, in striking contrast to our expectations. Thus,
these ﬁndings suggest that normal basal TTP expression is essential
also for the pro-inﬂammatory response in these cells, and raise the in-
teresting possibility of a ‘safety mechanism’ ensuring that when the
muscle cell is incapable of generating an anti-inﬂammatory response
in advance (due to reduced TTP expression, and maybe in other cases
as well), it limits the preceding inﬂammatory reaction in the ﬁrst
place.
Our microarray analysis revealed that the PO-induced changes in
mRNA processing factors and apoptosis-related transcripts were
mostly reversed or attenuated by six hours post-treatment. This is
in agreement with former studies of our group, indicating that the be-
havioral symptoms diminish at similar time points [36]. Importantly,
both AChE-R and PO injections inﬂuence the cholinergic state in the
NMJ, but also have other effects; PO injection leads to AChE inhibition
in the NMJ and in the muscle ﬁbers themselves [53], resulting in
higher levels of ACh and enhanced activation of muscle cholinergic
receptors [4]. However, PO also exerts cytotoxic effects which are in-
dependent of the cholinergic system [79]. Additionally, changes in
AChE levels, exerted by either direct AChE-R injection or by PO inhi-
bition, have implications outside the cholinergic system, due to
other cellular roles of AChE [4]. For example, lower levels of ACh in
the NMJ due to AChE-R injection may disrupt muscle cell survival,
but at the same time AChE-R itself is involved both in apoptotic [80]
and cell proliferation [81] processes in different tissues. Similarly,
higher levels of ACh in the NMJ due to PO injection are expected to
promote cell survival, but at the same time the cytotoxic effects of
PO induce cell death [82]. Accordingly, we detected AChE-R and PO-
mediated changes in apoptosis-related transcripts, but could not clas-
sify their total effect as pro- or anti-apoptotic. Intriguingly, when
AChE-R is injected together with PO, it does reverse many of PO-
mediated changes. Also, we detected a signiﬁcant correlation between
the AChE and PO effects on mRNA processing factors and apoptosis-
related transcripts, although these two treatments caused opposite cho-
linergic consequences. This could also be explained by the rapid feed-
back response induced by AChE inhibition [53,54], which encourages
AChE production
Three mRNA processing factors, namely Sf3a1, SRp55 and Rnpc2,
and one pro-apoptotic transcript (‘Fas-long’) were altered under ex-
cessive levels of AChE-R both in muscle tissues and neuronal precur-
sor cells. Moreover, all of these transcripts were signiﬁcantly changed
by excessive expression of the other, more prevalent AChE variant,
AChE-S, in P19 neuronal precursors [42]. Thus, these transcripts
may be regulated by cholinergic stimulation independently of the
physiological context. Muscarinic stimulation was shown to attenuate
Fas induction in myocytes following oxidative stress [83]. Moreover,
myasthenia gravis patients with anti-ACh receptor antibody have
higher proportion of thymocytes expressing higher levels of Fas [84].
Further research is needed to determine whether Fas expression is
globally affected by cholinergic signaling, and whether this control is
mediated by Clk1 and/or its target proteins.
Our investigation of changes in apoptotic-related transcripts
exerted by cholinergic-induced mRNA processing factors highlighted
a previously unknown regulation mechanism for the anti-apoptotic
gene, Mcl-1. Previous studies showed that Mcl-1 has a very short half-life time due to rapid degradation by the proteasome and caspases
[85,86]. Here, we emphasize the importance of post-transcriptional
processes such as alternative selection between different polyadenyla-
tion sites. Since 3′-UTRs are involved inmRNA stability and localization,
the differences between the resulting variants have fundamental effects
on Mcl-1 expression. Interestingly, recent studies suggest that cancer
cells and other proliferating cells tend to express mRNA isoforms with
shorter 3′-UTRs to escape from miRNA-mediated regulation [87,88].
Similarly, we identiﬁed a putative TTP binding element in the distal
part of Mcl-1 3′-UTR, raising the possibility that only the long variant
may be subjected to TTP-mediated degradation. Additionally, TTP ex-
pression was induced while the long variant of Mcl-1 was reduced in
PO treatedmuscles. Since Mcl-1 is an anti-apoptotic protein, and its ex-
pression is increased in several cancer cells [89], it is possible that these
cells also use the ‘strategy’ of switching to the short variant to escape
TTP regulation. Importantly, in several tissues, Mcl-1 transcription is
regulated by GM-CSF [90], which is a TTP target by itself [91]. However,
TTP did not totally eliminate Mcl-1 transcripts.
5. Conclusions
Our study sheds new light on cholinergic-dependent changes in
mRNA processing factors that control inﬂammation and apoptosis. It
introduces three novel ﬁndings: (1) Cholinergic stimulation has an
anti-inﬂammatory effect in muscle cells. (2) TTP is an essential mediator
of the cholinergic anti-inﬂammatory pathway in muscles. (3) The Mcl-1
gene has three functional polyadenylation sites, and can be regulated by
alternative selection among them under the inﬂuence of cholinergic
stimulation. Together, our results emphasize the role of ACh not only
as muscle activator, but also as a keeper of homeostasis in this tissue,
and explain why disruption of cholinergic stimulation to muscles, as in
myasthenia gravis or injuries, enhances inﬂammation and apoptosis.
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